Compile Data Set for Download or QSAR
Report error Found 220 Enz. Inhib. hit(s) with all data for entry = 8679
TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317904(US9624217, Compound 57 | US10399976, Compound 57 |...)
Affinity DataKi: <100nMAssay Description:Compounds of the present invention were tested for ability to bind to ROR gamma in a cell-free competition assay with commercially available radio-li...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317904(US9624217, Compound 57 | US10399976, Compound 57 |...)
Affinity DataIC50: 100nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317905(US9624217, Compound 58 | US10399976, Compound 58 |...)
Affinity DataKi: <100nMAssay Description:Compounds of the present invention were tested for ability to bind to ROR gamma in a cell-free competition assay with commercially available radio-li...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317901(US9624217, Compound 54 | US10399976, Compound 54 |...)
Affinity DataIC50: 100nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317902(US9624217, Compound 55 | US10399976, Compound 55 |...)
Affinity DataKi: <100nMAssay Description:Compounds of the present invention were tested for ability to bind to ROR gamma in a cell-free competition assay with commercially available radio-li...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317902(US9624217, Compound 55 | US10399976, Compound 55 |...)
Affinity DataIC50: 100nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317903(US9624217, Compound 56 | US10399976, Compound 56 |...)
Affinity DataKi: <100nMAssay Description:Compounds of the present invention were tested for ability to bind to ROR gamma in a cell-free competition assay with commercially available radio-li...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317901(US9624217, Compound 54 | US10399976, Compound 54 |...)
Affinity DataKi: <100nMAssay Description:Compounds of the present invention were tested for ability to bind to ROR gamma in a cell-free competition assay with commercially available radio-li...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM318006(US9624217, Compound 159 | US10399976, Compound 159...)
Affinity DataKi: <100nMAssay Description:Compounds of the present invention were tested for ability to bind to ROR gamma in a cell-free competition assay with commercially available radio-li...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317914(US9624217, Compound 67 | US10399976, Compound 67 |...)
Affinity DataKi: <100nMAssay Description:Compounds of the present invention were tested for ability to bind to ROR gamma in a cell-free competition assay with commercially available radio-li...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317914(US9624217, Compound 67 | US10399976, Compound 67 |...)
Affinity DataIC50: 100nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317911(US9624217, Compound 64 | US10399976, Compound 64 |...)
Affinity DataKi: <100nMAssay Description:Compounds of the present invention were tested for ability to bind to ROR gamma in a cell-free competition assay with commercially available radio-li...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317910(US9624217, Compound 63 | US10399976, Compound 63 |...)
Affinity DataKi: <100nMAssay Description:Compounds of the present invention were tested for ability to bind to ROR gamma in a cell-free competition assay with commercially available radio-li...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317905(US9624217, Compound 58 | US10399976, Compound 58 |...)
Affinity DataIC50: 100nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317906(US9624217, Compound 59 | US10399976, Compound 59 |...)
Affinity DataKi: <100nMAssay Description:Compounds of the present invention were tested for ability to bind to ROR gamma in a cell-free competition assay with commercially available radio-li...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317906(US9624217, Compound 59 | US10399976, Compound 59 |...)
Affinity DataIC50: 100nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317850(US9624217, Compound 3 | US10399976, Compound 3 | U...)
Affinity DataKi: <100nMAssay Description:Compounds of the present invention were tested for ability to bind to ROR gamma in a cell-free competition assay with commercially available radio-li...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317850(US9624217, Compound 3 | US10399976, Compound 3 | U...)
Affinity DataIC50: 100nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317851(US9624217, Compound 4 | US10399976, Compound 4 | U...)
Affinity DataKi: <100nMAssay Description:Compounds of the present invention were tested for ability to bind to ROR gamma in a cell-free competition assay with commercially available radio-li...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317851(US9624217, Compound 4 | US10399976, Compound 4 | U...)
Affinity DataIC50: 100nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317880(US9624217, Compound 33 | US10399976, Compound 33 |...)
Affinity DataKi: <100nMAssay Description:Compounds of the present invention were tested for ability to bind to ROR gamma in a cell-free competition assay with commercially available radio-li...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317880(US9624217, Compound 33 | US10399976, Compound 33 |...)
Affinity DataIC50: 100nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM412666(US10399976, Compound 2 | (S)-N-((5-(ethylsulfonyl)...)
Affinity DataKi: <100nMAssay Description:Compounds of the present invention were tested for ability to bind to ROR gamma in a cell-free competition assay with commercially available radio-li...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
US Patent
PDB3D3D Structure (crystal)
TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM412666(US10399976, Compound 2 | (S)-N-((5-(ethylsulfonyl)...)
Affinity DataIC50: 100nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
US Patent
PDB3D3D Structure (crystal)
TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317881(US9624217, Compound 34 | US10399976, Compound 34 |...)
Affinity DataKi: <100nMAssay Description:Compounds of the present invention were tested for ability to bind to ROR gamma in a cell-free competition assay with commercially available radio-li...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317857(US9624217, Compound 10 | US10399976, Compound 10 |...)
Affinity DataKi: <100nMAssay Description:Compounds of the present invention were tested for ability to bind to ROR gamma in a cell-free competition assay with commercially available radio-li...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317854(US9624217, Compound 7 | US10399976, Compound 7 | U...)
Affinity DataKi: <100nMAssay Description:Compounds of the present invention were tested for ability to bind to ROR gamma in a cell-free competition assay with commercially available radio-li...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317855(US9624217, Compound 8 | US10399976, Compound 8 | U...)
Affinity DataKi: <100nMAssay Description:Compounds of the present invention were tested for ability to bind to ROR gamma in a cell-free competition assay with commercially available radio-li...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317852(US9624217, Compound 5 | US10399976, Compound 5 | U...)
Affinity DataKi: <100nMAssay Description:Compounds of the present invention were tested for ability to bind to ROR gamma in a cell-free competition assay with commercially available radio-li...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317852(US9624217, Compound 5 | US10399976, Compound 5 | U...)
Affinity DataIC50: 100nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM412670(US10399976, Compound 6 | (S)-N-(4-(ethylsulfonyl)b...)
Affinity DataKi: <100nMAssay Description:Compounds of the present invention were tested for ability to bind to ROR gamma in a cell-free competition assay with commercially available radio-li...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
7/27/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317869(US9624217, Compound 22 | US10399976, Compound 22 |...)
Affinity DataKi: <100nMAssay Description:Compounds of the present invention were tested for ability to bind to ROR gamma in a cell-free competition assay with commercially available radio-li...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317869(US9624217, Compound 22 | US10399976, Compound 22 |...)
Affinity DataIC50: 100nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317849(US9624217, Compound 2 | (S)-N-((5-(ethylsulfonyl)...)
Affinity DataKi: <100nMAssay Description:Compounds of the present invention were tested for ability to bind to ROR gamma in a cell-free competition assay with commercially available radio-li...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317849(US9624217, Compound 2 | (S)-N-((5-(ethylsulfonyl)...)
Affinity DataIC50: 100nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317864(US9624217, Compound 17 | US10399976, Compound 17 |...)
Affinity DataKi: <100nMAssay Description:Compounds of the present invention were tested for ability to bind to ROR gamma in a cell-free competition assay with commercially available radio-li...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317864(US9624217, Compound 17 | US10399976, Compound 17 |...)
Affinity DataIC50: 100nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317956(US9624217, Compound 109 | US10399976, Compound 109...)
Affinity DataKi: <100nMAssay Description:Compounds of the present invention were tested for ability to bind to ROR gamma in a cell-free competition assay with commercially available radio-li...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM412679(US10399976, Compound 15)
Affinity DataKi: <100nMAssay Description:Compounds of the present invention were tested for ability to bind to ROR gamma in a cell-free competition assay with commercially available radio-li...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
7/27/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317877(US9624217, Compound 30 | US10399976, Compound 30 |...)
Affinity DataIC50: 100nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317878(US9624217, Compound 31 | US10399976, Compound 31 |...)
Affinity DataKi: <100nMAssay Description:Compounds of the present invention were tested for ability to bind to ROR gamma in a cell-free competition assay with commercially available radio-li...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317878(US9624217, Compound 31 | US10399976, Compound 31 |...)
Affinity DataIC50: 100nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317879(US9624217, Compound 32 | US10399976, Compound 32 |...)
Affinity DataKi: <100nMAssay Description:Compounds of the present invention were tested for ability to bind to ROR gamma in a cell-free competition assay with commercially available radio-li...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317875(US9624217, Compound 28 | US10399976, Compound 28 |...)
Affinity DataIC50: 100nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317876(US9624217, Compound 29 | US10399976, Compound 29 |...)
Affinity DataKi: <100nMAssay Description:Compounds of the present invention were tested for ability to bind to ROR gamma in a cell-free competition assay with commercially available radio-li...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317876(US9624217, Compound 29 | US10399976, Compound 29 |...)
Affinity DataIC50: 100nMAssay Description:Compounds of the present invention were tested for ROR gamma inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317877(US9624217, Compound 30 | US10399976, Compound 30 |...)
Affinity DataKi: <100nMAssay Description:Compounds of the present invention were tested for ability to bind to ROR gamma in a cell-free competition assay with commercially available radio-li...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317874(US9624217, Compound 27 | US10399976, Compound 27 |...)
Affinity DataKi: <100nMAssay Description:Compounds of the present invention were tested for ability to bind to ROR gamma in a cell-free competition assay with commercially available radio-li...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317875(US9624217, Compound 28 | US10399976, Compound 28 |...)
Affinity DataKi: <100nMAssay Description:Compounds of the present invention were tested for ability to bind to ROR gamma in a cell-free competition assay with commercially available radio-li...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317871(US9624217, Compound 24 | US10399976, Compound 24 |...)
Affinity DataKi: <100nMAssay Description:Compounds of the present invention were tested for ability to bind to ROR gamma in a cell-free competition assay with commercially available radio-li...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
US Patent

Displayed 1 to 50 (of 220 total ) | Next | Last >>
Jump to: